However, the clinical implications of CTLA-4 expression in tumors or immune cells in the tumor microenvironment are still controversial, and the potential for CTLA-4 as a prognostic marker has been complicated by differences in study populations and methods. The gene discussed is CTLA4; the disease is neoplasm.